| Identification | Back Directory | [Name]
GAL-021 | [CAS]
1380341-99-0 | [Synonyms]
GAL-021
GAL-021, >98%
GAL021;GAL 021
GAL-021, 1380341-99-0
1,3,5-Triazine-2,4,6-triamine, N2-methoxy-N2-methyl-N4,N6-dipropyl- | [Molecular Formula]
C11H22N6O | [MDL Number]
MFCD31657265 | [MOL File]
1380341-99-0.mol | [Molecular Weight]
254.33 |
| Chemical Properties | Back Directory | [Boiling point ]
390.6±25.0 °C(Predicted) | [density ]
1.164±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 3 mg/ml; DMSO: 5 mg/ml; Ethanol: Slightly soluble; PBS (pH 7.2): 0.30 mg/ml | [form ]
A crystalline solid | [pka]
7.07±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates[1][2]. | [in vivo]
Intravenously administered GAL-021 attenuates opiate-induced respiratory depression in rats and nonhuman primates without affecting analgesia in rats. GAL-021 ventilatory stimulation in rats is attenuated by carotid sinus nerve transection. GAL-021 ventilatory stimulation is attenuated in mice lacking the pore-forming α-subunit of the KCa 1.1 channel[1]. | [References]
[1] Golder FJ, et al. Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator. Anesthesiology. 2015 Nov;123(5):1093-104. DOI:10.1097/ALN.0000000000000844
[2] J F McLeod, et al. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br J Anaesth. 2014 Nov;113(5):875-83. DOI:10.1093/bja/aeu182 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|